Nov 12, 2020 8:30 am EST Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)
Nov 09, 2020 4:01 pm EST Atara Biotherapeutics Announces Third Quarter 2020 Financial Results and Operational Progress
Nov 02, 2020 4:01 pm EST Atara Biotherapeutics to Announce Third Quarter 2020 Financial Results on Monday, November 9, 2020
Sep 14, 2020 8:30 am EDT Atara Biotherapeutics To Present Clinical Data in Epstein-Barr Virus-Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID-LPD and PID-LPD) from Tab-Cel® Expanded Access Program in e-Poster at ESMO 2020 Virtual Congress
Sep 11, 2020 8:00 am EDT Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188
Sep 08, 2020 7:00 am EDT Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors
Sep 01, 2020 7:00 am EDT Atara Biotherapeutics to Present 12-Month Data from All Four Cohorts in the Phase 1a Study of ATA188 in Progressive Multiple Sclerosis at MSVirtual2020
Aug 05, 2020 4:01 pm EDT Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress
Jul 29, 2020 4:01 pm EDT Atara Biotherapeutics to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020
Jun 24, 2020 4:34 pm EDT Atara Biotherapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares